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with possible TF approach was substantially higher (70.2%). In the remaining 29.8%
not treatable using this AW, 48.4% fulfilled the anatomical criteria regarding the SA.
In summary, 84.6% of patients provide suitable AW for “conventional” TAVI with the
MCV.
Conclusion: The majority of patients with AVS scheduled for TAVI show sufficient
AW for “conventional” TAVI with the MCV. Anyhow, a substantial number of patients
are not eligible due to inappropriate AW. Consecutively, the retrograde trans-aortic
AW, which is rarely performed, may be an option to solve this problem.
TCT-728
Sutureless Implantation of a Expandable Mitral Stent-Valve Prosthesis in Acute
Animal Model
Jose Luis Navia, Ji-Feng Chen, Shengqiang Gao, Qun Zhou, Leonardo Rodriguez,
Nicolas Brozzi, Jamshid Karimov, Kiyotaka Fukamachi
Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH
Background: Minimally-invasive and transcatheter approaches have become very
popular particularly for aortic valve procedures. While the former continues to improve
the operative technique, the application of catheter-delivery technologies in selected
high risk patients is becoming more and more challenging. This is more specifically
true for patients with mitral regurgitation who present a burgeoning clinical unmet
need for therapeutic advances and a transcatheter implanted mitral valve may offer a
very effective treatment alternative and this begins with the sutureless implantation of
such device.
Methods: This study describes the initial results of the feasibility study of the sutureless
implantation of mitral valve prostheses in an acute ovine model. The device consists
of a pericardial bioprosthetic valve mounted within a expandable support structure.
The device is collapsed radially and balloon expanded radially, thereby providing a
secure attachment to the valve annulus without requiring sutures. The new stent-valve
was designed for a prospective catheter delivered implantation technique. The stent-
valves were deployed in the mitral annular position, through a left thoracotomy access,
cardiopulmonary bypass (CPB) institution and direct valve implantation in a beating
heart.
Results: All valves were successfully implanted. Echocardiographic assessment
confirmed excellent function of the bioprosthetic mitral valve with accurate positioning
and secure anchoring of the stent-valve onto the mitral annulus. Even at the highest
registered systolic AoP (>200 mmHg) with its attendant extreme dP/dt, there was no
dislocation of any part or the valve. No perivalvular leak or central mitral regurgitation
was observed. Confirmation of a clear unobstructed LVOT with preservation of the
subvalvular apparatus. Valve function evidenced normal hemodynamic performance
and pressure gradient across the implanted valve.
Conclusion: The new design of a contractible and expandable mitral valve prosthesis
demonstrated reliable valve performance, secure engagement of the native annulus
confirms the feasibility and suggests potential ease of implantation. Further chronic
study is needed to verify these results and evaluate reliability of implantation
procedures, biocompatibility, and valve durability. This signals that transition to a
transcatheter valve delivery may be eased by the attributes of this new device.
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Reduced incidence of bleedings, vascular complications and 30 days mortality
with the Sapien Novaflex system: Results from a single center Tansfemoral-
TAVI registry
Giovanni Sorropago, Eugenio Stabile, Armando Pucciarelli, Linda Cota, Angelo
Cioppa, Marco Agrusta, Vittorio Ambrosini, Vincenzo Lucchetti, Paolo Rubino
clinica montevergine, Mercogliano, Italy
Background: Transcatheter aortic valve implantation (TAVI) is performed via the
trans-femoral (TF) route as the first choice delivery approach with encouraging results
from worldwide registries. Vascular access management is a major challenge in TF
TAVI due to the need for large-sized introducer sheaths. Bleedings are common
complications of the TAVI procedure are related to sheath size. The new generations
of TAVI systems are significatively smaller than the first generation systems.In this
study we report the incidence of bleedings in patients undergoing TAVI in a single
centre institution.
Methods: From June 2008 to May 2011, a total of 156 patients in our institutions
underwent TAVI using the TF approach. Patients were divided into two groups
according to the TAVI system adopted: Group A (Retroflex, Edwards Life Sciences)
and Group B (Novaflex, Edwards Life Sciences). Patients received a detailed clinical
assessment and serial blood testing before and one hour, twenty four hours and at
discharge after TAVI. At one month patients underwent a clinical follow up visit.
Bleedings and vascular complications were classified according to the VARC criteria.
Results: At 30 days the incidence of mayor and minor vascular complications was
significatively lower in group B (p<0.05). No distal embolizations occurred in any of
the groups. The reduced incidence of vascular complications was associated with a
reduced incidence of Life-Threatening Bleedings, Mayor Bleedings and Minor
bleedings were significatively, in group B (p<0.05). Overall this resulted into a
significative reduction in 30 days mortality (7.7 % vs 1.6%, (p<0.05) and in particular
annealed the occurrence of vascular related.
Conclusion: The use of the Novaflex system allowed a reduction of post TAVI
bleedings, vascular complications, vascular related deaths and 30 mortality. This data,
if confirmed in a large metacentre registry, would further support the diffusion of TAVI
for the treatment of patients with severe aortic stenosis and at high surgical risk.
TCT-730
Transcranial Doppler Analysis of Embolic Events during Transcatheter Aortic
Valve Implantation
William T Brinkman1, Karen L Roper1, Rebeca Kim1, Morley A Herbert2, Stuart J
Head3, Ashley M Stone1, Todd M Dewey2, 1, Michael J Mack1
1CRSTI, Dallas, TX; 2Medical City Dallas, Dallas, TX; 3Erasmus University Medical
Center, Rotterdam, Netherlands
Background: Neurologic impairment post AVR correlates with Transcranial Doppler
(TCD)-measured embolic high intensity signals (HITS), but less is known about their
occurrence in the transcatheter-based aortic valve insertion (TAVI) procedures where
risk for stroke is reported to be higher. This study compares HITS across common
events during TF-transfemoral and TA-transapical TAVI.
Methods: Output from TCD provided time-stamped HITS detection and artifacts
rejection. Procedural events were marked throughout TAVI-TF (n=21) and TAVI-TA
(n=21). HITS during BAV- and Valve- delivery System Intervals (B-SI and V-SI) were
then compared. Balloon delivery system (TF) or apical sheath insertion (TA) marked
B-SI start. VS-I was initiated (and B-SI ended) with insertion of the valve delivery
system (into the arch for TF and into the apex for TA). VS-I ended when 60 seconds
had passed following valve delivery system removal (TF) or apical sheath removal
(TA). Specific events within each interval were also compared, with HITS counted for
60sec following each.
Results: Though not significant (p=0.1), total HITS were greater in TAVI-TF (674)
than TA (542). In both procedures, V-SI created more emboli than B-SI (p<0.001).
Subdivision of the events during VS-I revealed a larger number of HITS during valve
deployment in TF than TA (p< .01). Advancement of the valve across the aortic arch
(unique to TF) also contributed. B-SI HITS were highest during TA insertion of the
apical sheath.
Conclusion: Patients are at more risk for embolic events during valve deployment than
during BAV. TAVI procedures may benefit from an intravascular filter prior to delivery
across the aortic arch in TF and placement prior to apical sheath insertion in TA.
TCT-731
Clinical and functional outcome after transapical aortic valve implantation
using the JenaValveTM AVR System – Results of the first-in-man study after one
year
Ardawan J Rastan1, Joerg Kempfert1, Thomas Walther1, Hans R Figulla2, Markus
Ferrari2, Gerhard Schuler1, Martin Haensig1, Axel Linke1, Katrin Leadley3, Andreas
Marx3, David M Holzhey1, Friedrich W Mohr1
1Heart Center, University of Leipzig, Leipzig, Germany; 2Department of Cardiology,
University of Jena, Jena, Germany; 3JenaValve Technology GmbH, München,
Germany
Background: To evaluate the feasibility, safety and valve performance of the
JenaValveTM for transapical transcatheter aortic valve implantation (TAVI) during the
first-in-man (FIM) study.
Methods: The JenaValveTM aortic valve replacement (AVR) TAVI System is composed
of a porcine xenograft attached on a self-expandable Nitinol stent. It allows precise
anatomical valve orientation by three positioning arms. The stent design anchoring the
native leaflets, the sub-coronary position and the possibility of retrieving the valve
before final release provide potential advantages compared to current TAVI systems.
Between 07/09 and 04/2010 twelve patients were enrolled. Mean age was 85.9±4.0
years, all patients were female, log EuroSCORE was 24.7±10.5% and STS score was
10.3±4.3. Native annulus size was 21.4±1.2mm. The procedure was aborted in one
patient due to acute type A dissection and in two patients because the positioning arms
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could not be completely released. These shortcomings were addressed by redesigning
the catheter tip.
Results: Nine patients underwent an uneventful procedure without conversion and
reached the primary 30-day endpoint. Mean procedure time was 101±21min, contrast
dye exposition was 135±73ml and post-dilatation was necessary in 3 patients. After
one year maximal and minimal valve gradients were 15.7±4.8 and 7.5±1.6 mmHg,
respectively. None of the patients had more than trivial paravalvular leak, none needed
pacemaker implantation. After follow-up of 389±195 days, three patients died on none
valve related causes.
Conclusion: After redesign of the delivery system the JenaValveTM AVR System
allowed safe and precise anatomical valve implantation with good valve performance
and no atrioventricular block up to one year after implantation.
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Transcatheter aortic valve replacement with a self-expandable bioprosthesis
performed without balloon valvuloplasty: comparative results in a consecutive
series of patients
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A.C Abizaid1, Rodrigo Barreto1, 2, Magali Arrais1, 2, Auristela Ramos1, 2, Manuel N
Cano1, 2, Antonio Kambara1, 2, Adriana C Moreira2, Jorge Assef1, Fausto Feres1, 2,
Eberhard Grube1, Amanda GMR Sousa1, 2, J. Eduardo M.R. Sousa1, 2
1Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil; 2Hospital do Coração
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Background: Balloon aortic valvuloplasty (BAV) is currently recommended as an
indispensable step before transcatheter aortic valve replacement (TAVR), in order to
facilitate crossing of the stenotic native valve and to provide adequate positioning and
expansion of a bioprosthesis. However, BAV is not a risk-free procedure, and might
be associated with aortic dissection, stroke, severe aortic regurgitation and conduction
disturbances. We aimed to describe our preliminary experience in TAVR with a self-
expandable prosthesis (CoreValve®, Medtronic Inc.) performed without BAV.
Methods: Single-center, prospective, non-randomized registry of consecutive pts
selected from Sept/09 to Apr/11 to TAVR with TEE monitoring. Pts were divided in
groups accordingly to BAV utilization (A: without BAV and B: with BAV). Procedure
success and clinical outcomes (VARC) were determined, and mean/max gradients,
valve area and expansion and severity of aortic regurgitation after TAVR were analysed
by TEE.
Results: A total of 50 pts were enrolled. Mean age was 82.3 ± 1.4 yrs, 71% were
female, STS score was 11.2 ± 3.4 and logistic Euroscore was 26.8 ± 8.4%. Twenty-
one pts were initially scheduled to TAVR without predilation, and 29 pts to TAVR with
BAV. In 3 pts scheduled to TAVR without BAV (all with LVEF <40% and aortic valve
area <0.7 cm2), severe hypotension occurred after crossing the stenotic valve with the
18F delivery system, and BAV was required. No clinical and anatomic differences (as
determined by TEE and CTA) were observed between groups. Balloon post-dilation
was performed in 7 pts (39%) in group A and in 9 pts (28%) in B. No significant
differences in clinical outcomes were noted. TTE/TEE measurements after TAVR were
shown below.
Conclusion: In this pilot study, TAVR with a self-expandable prosthesis performed
without BAV was feasible and resulted in similar performance as compared to currently
recommended TAVR with predilation. The possibility of hemodynamic disturbance
(particularly in pts with depressed LV function and critically reduced aortic valve area)
should not be overlooked.
TCT-733
The Ratio Between Bioprosthesis and CT-Measured Mean Annulus Diameter
Predicts Significant Post-Procedural Aortic Regurgitation in Transcatheter
Aortic Valve Implantation
Kentaro Hayashida, Erik Bouvier, Thierry Lefevre, Thomas Hovasse, Marie-Claude
Morice, Bernard Chevalier, Mauro Romano, Philippe Garot, Arnaud Farge, Patrick
Donzeau-Gouge, Bertrand Cormier
Institut Cardiovasculaire Paris Sud, Massy, France
Background: The impact of CT-scan on Post-procedural aortic regurgitation (AR) still
remains controversial. The purpose of this study was to identify the predictors for post-
procedural AR including CT-scan indices.
Methods: Among 337 consecutive TAVI cases in our institution, cardiac CT-scan to
asses precisely the annulus size was performed in the last 109 cases. The CT-measured
mean annulus diameter was calculated as: mDiam-CT=2√(annulus surface/√). The
clinical, echographic and CT-scan characteristics were to identify the predictors for
post-procedural AR ≥2.
Results: Patients were 83.5±5.8 years old with a logistic Euroscore of 23.9±11.5%.
The Edwards valve was used in 92 cases (23mm in 32%, 26mm 58% and 29mm 19%)
and Corevalve in 17 (26mm in 29% and 29mm in 71%). Univariate analysis identified
lower body mass index (25.0±3.8 vs 26.1±4.6, p=0.048), smaller aortic valve area
(0.56±0.13 vs 0.62±0.15, p=0.002), lower grade of pre-procedural AR (0.73±0.71 vs
0.93±0.71, p=0.033), a smaller valve diameter/mDiam-CT ratio” (1.08±0.07 vs
1.12±0.06, p=0.008) and valve diameter/largest Diam-CT ratio” (0.97±0.07 vs
1.01±0.06, p=0.018), transapical approach (22.7 vs 35.7%, p=0.019) and transaortic
approach (0 vs 5.1%, p<0.001) significantly associated with post-procedural AR ≥2.
Calcification score of annulus and valve by CT, “the valve / smallest Diam-CT ratio”
and “the valve / Diam-TEE ratio” were not associated with post-procedural AR.
Multivariate analysis revealed “the valve / mDiam-CT ratio” to be the only independent
predictor for post-procedural AR ≥2 (HR 0.909 by increase of 0.01, 95%CI: 0.837-
0.987, p=0.023). A valve / mDiam-CT ratio threshold of 1.10 (AUC=0.688) predicted
a higher rate of post-procedural AR ≥2 (29.8% vs 11.3%, p=0.015).
Conclusion: The ratio between valve size / mDiam-CT was more accurate than Diam-
TEE to predict post-procedural AR. Further application of CT-scan may decrease the
risk of AR.
TCT-734
Predictors and Clinical Outcome of Patients with Acute Kidney Injury
Following Trans-Cutaneous Aortic Valve Replacement
Israel M Barbash, Itsik Ben-Dor, Gabriel Maluenda, Paul J Corso, Steven A
Goldstein, Zuyue Wang, Rebecca Torguson, Lowell F Satler, Augusto D Pichard, Ron
Waksman
Cardiology Dept., Washington Hospital Center, Washington, DC
Background: Post-procedural acute kidney injury (AKI) is a poor prognostic factor.
Data on incidence and prognostic impact of AKI post-TAVR are scarce and ranges
from 19-28%. Our aim was to identify predictors and assess the prognostic effect of
AKI post-TAVR.
Methods: Consecutive aortic stenosis patients undergoing TAVR (trans-femoral,
n=103; trans-apical (TA), n=47) were retrospectively analyzed. Post-TAVR AKI was
defined as increase in serum creatinine ≥0.3 mg/dL or ≥ X1.5 (<72 hrs) (VARC
definition) or >25% reduction in GFR (MDRD) (<48 hrs) (GFR) as compared with
baseline.
Results: Post-TAVR AKI occurred in 22 (14.6%) of the patients (according to VARC),
and in 11 (7.3%) patients (according to GFR). At discharge, creatinine levels
normalized in 15 (68%) of the patients. Two patients (1.3%) required temporary renal
replacement therapy. Demographics of patients who developed AKI were comparable
to Non-AKI patients. (Table) AKI patients were more likely to have TA TAVR and
general anesthesia (Table). In multivariable analysis PVD (OR 2.62, 95%CI 0.95-7.28),
and trans-apical TAVR (OR 2.41, 95%CI 0.88-6.63) showed borderline significance
for association with AKI. AKI patients required longer ICU stay (64 vs. 177 hrs;
p=0.01) and suffered higher in-hospital (4% vs. 27%; p=0.001) and 30-day mortality
(7% vs. 41%; p <0.001).
Conclusion: Even a small (0.3 mg/dL) increase in baseline creatinine post-TAVR is
associated with worse outcome. Patients with PVD who are selected for TA TAVR
should be managed more carefully in order to prevent AKI.
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